Naronapride Eases Gastroparesis Symptoms in Phase 2 Trial
Summary
Naronapride, an investigational prokinetic, leads to greater improvements in gastroparesis symptoms than placebo when administered at 20 and 40 mg three times daily, a phase 2 trial shows.
Description from Medscape.
Who is covering this
-
Naronapride Eases Gastroparesis Symptoms in Phase 2 Trial
Naronapride, an investigational prokinetic, leads to greater improvements in gastroparesis symptoms than placebo when administered at 20 and 40 mg three times daily, a phase 2 trial shows.
